A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Philippos Apolinario Costa, Mary Josephine Paula Pilat, Jordi Rodon Ahnert, Melissa Amber Burgess, Gabriel Tinoco, Julia Lee Close, Roman Groisberg, Vivek Subbiah, Benjamin Powers, Candace L. Haddox, Juneko Grilley-Olson, Vicki Leigh Keedy, Jing Li, S. Percy Ivy, Abhijit Patel, Geoffrey Ira Shapiro, Jeffrey Joseph Ishizuka, Kurt A. Schalper, Patricia LoRusso
Institutions: Yale Cancer Center, Wayne State University, The University of Texas MD Anderson Cancer Center, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, University of Florida, Rutgers, The State University of New Jersey, Rutgers Cancer Institute, University of Kansas Medical Center, Dana-Farber Cancer Institute, Duke University, Duke Cancer Institute, Vanderbilt University Medical Center, Atrium Health Wake Forest Baptist, Wake Forest Baptist Comprehensive Cancer Center, National Institutes of Health, National Cancer Institute, Yale University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410812937